| Budget Amount *help |
¥17,810,000 (Direct Cost: ¥13,700,000、Indirect Cost: ¥4,110,000)
Fiscal Year 2015: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2014: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2013: ¥6,630,000 (Direct Cost: ¥5,100,000、Indirect Cost: ¥1,530,000)
|
|---|
| Outline of Final Research Achievements |
Oncoantigen are tumor antigens required for the neoplastic process and when cancer vaccine against oncoantigen, the chance that escape immune recognition to tumor should be reduced. In order to identify oncoantigens against glioma, we performed the comparative gene expression analysis of gliomas and also gene expression analysis of known oncoantigens against other cancers in gliomas. Then, functional analysis of oncoantigen candidates selected was performed in glioma cells. We succeeded in identify two oncoantigens against glioma that are expressed highly in malignant glioma tissues, glioma cell lines, and glioma stem cells isolated from glioma patients. These oncoantigens were shown to be involved in the growth of glioma by gene knockdown experiments. Furthermore, in a mouse in vivo glioma model, the gene knockdown of the oncoantigen showed a significant therapeutic effect. We plan to perform an immunotherapy using the oncoantigen identified for the treatment of malignant gliomas.
|
